Joined in 2023 
82 
63 About this deal
Personally i'm willing to give it a go when it's fully approved if its cheap enough but only alongside my current regimen. The data is segmented by drug name and intervention type and shows the current likelihood of approval for the drug compared to both the indication benchmark and the industry benchmark so you can:
Pyrilutamide KX-826 | Ligand Chem, UK, Europe, America
Poster: Phase II clinical trial to evaluate the safety and efficacy of frittan (KX-826) tincture in the treatment of androgenetic alopecia (AGA) in Chinese adult males (KX-826-CN-1002). (2022). Kintor. This clinical study was done to evaluate the safety, tolerability, and pharmacokinetics of the topical AR antagonist, pyrilutamide, following multiple ascending dose administrations of 3mg, 12mg, 48mg, and 96mg. Dominguez‐Santas M, Diaz‐Guimaraens B, Saceda‐Corralo D, Hermosa‐Gelbard A, Muñoz‐Moreno Arrones O, Pindado‐Ortega C, Fernandez‐Nieto D, Jimenez‐Cauhe J, Ortega‐Quijano D, Suarez‐Valle A, Jaen‐Olasolo P. (2022). The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms. JEADV Clinical Practice. GlobalData’s Drug-Specific Likelihood of Approval (LoA) models utilizes many attributes from Drugs, Clinical Trials, Review Designations and Company. The proprietary, machine learning algorithm is developed based on the impact of a specific attribute on PTSR and LoA. I could be incorrect but my understanding was that the topical nature of the product is supposed to keep it localised to the scalp AR that the DHT would usually bind to causing the hair loss.
Store in a cool, dark place. Pyrilutamide solution maintains potency for at least two years upon mixing. Expiry date is displayed on label and only bottles with one year or more before this are shipped.
Pyrilutamide KX826 and Hair Growth | The Hair Loss Show Pyrilutamide KX826 and Hair Growth | The Hair Loss Show
The blood concentration of pyrilutamide among the subjects remained extremely low throughout the study. In terms of safety, there were no associated severe adverse drug events. Phase-2 clinical trials The drug innovator is Kintor Pharmaceutical Limited, known for developing and commercializing innovative treatments for androgen receptor-related diseases like androgenetic alopecia, acne vulgaris, and certain cancers. have also tried other treatments like castor oil, stemoxydine, tretinoin which had next to no benefit.
From Our Partners
Kinter, K. J., & Anekar, A. A. (2022). Biochemistry, dihydrotestosterone. In StatPearls [Internet] . StatPearls Publishing. Use PTSR and LOA information and event driven changes for your investment decisions to generate alpha A recently completed phase-1 clinical trial done in the US was a randomized, double-blind, placebo-controlled, parallel-group, and dose-escalation study. It involved 40 healthy adult male patients with androgenetic alopecia.
Kintor Pharma says alopecia primary endpoint met - Labiotech.eu
I did some reading. So this is topical? How much is the systemic absorption? I would not take an anti androgen orally as a male. It would have a castrating effect. If topical, biggest worry and need to know would be plasma concentration. it would work similar to topical spironolactone Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met. Accessed online: https://www.prnewswire.com/news-releases/kintor-pharma-announced-the-primary-endpoint-of-phase-ii-clinical-study-for-kx-826s-treatment-of-female-androgenetic-alopecia-in-china-was-met-301691321.html COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.” KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has demonstrated clinically meaningful and statistically significant improvement in hair growth. Kintor Pharmaceutical Limited has announced results of a phase II clinical trial of pyrilutamide (KX-826), a potential first-in-class topical drug, for the treatment of adult female androgeneticalopecia (AGA).Unfortunately a holy grail treatment you take once and are cured of hair loss is probably many, many decades away so it's either take what you have now or just get on with things as nature takes its course. Results of Kintor’s Phase Ib Clinical Trials of Pyrilutamide in America, Kintor Pharmaceutical Limited (2022). Accessed online: https://en.kintor.com.cn/news/129.html The study reported that applying 5 milligrams of pyrilutamide twice a day produced the best improvements in hair growth, increasing hair count by 22.73 hairs per cm ² after 24 weeks of treatment. In comparison to the placebo group’s hair count, the twice-a-day 0.5% concentration of pyrilutamide increased hair counts by 15.34 hairs per cm ² . (4-6)
Great Deal 
New Comment